234 related articles for article (PubMed ID: 15851712)
1. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Zhou Z; Rahme E; Abrahamowicz M; Tu JV; Eisenberg MJ; Humphries K; Austin PC; Pilote L
CMAJ; 2005 Apr; 172(9):1187-94. PubMed ID: 15851712
[TBL] [Abstract][Full Text] [Related]
2. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
3. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Andrews TC; Ballantyne CM; Hsia JA; Kramer JH
Am J Med; 2001 Aug; 111(3):185-91. PubMed ID: 11530028
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
5. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
6. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
7. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
Foody JM; Rathore SS; Galusha D; Masoudi FA; Havranek EP; Radford MJ; Krumholz HM
J Am Geriatr Soc; 2006 Mar; 54(3):421-30. PubMed ID: 16551308
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
9. Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Rinfret S; Behlouli H; Eisenberg MJ; Humphries K; Tu JV; Pilote L
Am Heart J; 2008 Feb; 155(2):316-23. PubMed ID: 18215603
[TBL] [Abstract][Full Text] [Related]
10. Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Choudhry NK; Levin R; Winkelmayer WC
Heart; 2007 Aug; 93(8):945-51. PubMed ID: 17344334
[TBL] [Abstract][Full Text] [Related]
11. Variable influence of statins on isoprostanes in hyperlipidemia.
Sinzinger H; Oguogho A
Adv Exp Med Biol; 2003; 525():209-12. PubMed ID: 12751770
[No Abstract] [Full Text] [Related]
12. Differences between statins on clinical endpoints: a population-based cohort study.
Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
[TBL] [Abstract][Full Text] [Related]
13. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
14. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
15. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
Perreault S; Blais L; Dragomir A; Bouchard MH; Lalonde L; Laurier C; Collin J
Eur J Clin Pharmacol; 2005 Oct; 61(9):667-74. PubMed ID: 16151763
[TBL] [Abstract][Full Text] [Related]
16. Risk of incident diabetes among patients treated with statins: population based study.
Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
[TBL] [Abstract][Full Text] [Related]
17. Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Lachaine J; Rinfret S; Merikle EP; Tarride JE
Am Heart J; 2006 Jul; 152(1):164-9. PubMed ID: 16824851
[TBL] [Abstract][Full Text] [Related]
18. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
19. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
[TBL] [Abstract][Full Text] [Related]
20. Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Doggrell SA
Rev Recent Clin Trials; 2006 May; 1(2):143-53. PubMed ID: 18473965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
